| HPV testing | |
|
The demand for a large-scale HPV screening and typing of the female population is indeed recognized by
national and international European health institutions and several countries are going to introduce HPV DNA
testing into the cervical cancer screening programs. The use of HPV DNA testing can provide women the opportunity for early screening programmes and detection of the cause of the cervical lesions. The availability of high accuracy cheap tests will allow screening on a larger population, enhancing the cervix cancer prevention policies. Furthermore, these methods will indeed offer a cost-effective solution for the validation of the new vaccine against HPV (cheap tests reduce the vaccine validation costs), thus having a reduced economic load on the EC. Hospitex Diagnostics propose two solutions for HPV testing: Present: Auto PCR Platform 
Robotic platform able to perform an automatic PCR for a general screening of HPV in cytological samples, and also specific detection of 33 of the most dangerous HPV subtypes. PCR products are revealed by using an automatic hybridization colorimetric approach, characterized by the hybridization of the PCR products with specific oligonucleotide probes which occur on three-dimensional porous matrixes rather than planar surfaces with the rapid "Flow-through" processes. Future: The NANO-MUBIOP Project 
NANO-MUBIOP (Enhanced sensitivity Nanotechnology-based Multiplexed Bioassay Platform for diagnostic applications) is a 7th FP funded EU project, coordinated by an Italian SME (Hospitex Diagnostics srl) active in the field of IVD and including 7 other partners: Pasteur Institute (France), NCSR-DCU (Ireland), MIG-INRA (France), Xennia Technology (UK), URATIM (Hungary), LENS (Italy) and Biochemistry Dept.-University of Florence (Italy). The aim of the NANO-MUBIOP project is to develop a high sensitivity platform based on bio-non bio nanostructures. This platform will be primarily designed for detecting the several genotypes of HPV. The proposed method will also have an estimated cost reduction of more than 50% with a strong impact from the final user point of view. Private/public national or local health service providers will get benefits from NANO-MUBIOP. The costs will be strongly reduced also for the patients. The project has been started the 1st of October 2008 with the kick-off meeting held in Florence (Italy) and will be completed by September 2011. Project Website: www.nanomubiop.eu The “HPV testing” section will be more detailed soon and fully completed by the end of 2009. |
|
 |
 |
 |